In Brief: Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy

CONCLUSION —Tafamidis(Vyndaqel; Vyndamax) can decrease the number of hospitalizations and deaths in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Taking 20 mg ofVyndaqel daily appears to be as effective as 80 mg and costs much less. Long-term data on the comparative efficacy of the two doses are not available.MA Gertz et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66:2451.FL Ruberg and JL Berk. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 126:1286.MS Maurer et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379:1007.FDA summary review. Vyndaqel (tafamidis meglumine). Available athttp://bit.ly/2RO4s7F. Accessed December 16, 2019.

Source: The Medical Letter - December 16, 2019 Category: Drugs & Pharmacology Authors: admin Tags: inotersen Onpattro patisiran tafamidis Tegsedi Vyndaqel Vyndmax Source Type: research